ChinaAMC Hang Seng Biotech ETF (03069.HK) Rises 4.12% Intraday as ESMO Congress with 28 Chinese Late-Breaker Studies Nears

NewTimeSpace News: As of 9:43 on October 16, the ChinaAMC Hang Seng Biotech ETF (03069.HK) rose 4.12% to a latest price of HK$15.430. The ETF has traded 1.0442 million units so far today for a turnover of HK$16.0134 million at an average price of HK$15.335, with a turnover rate of 0.442%. It is down 2.65% so far this week. Its current net asset value per unit is HK$14.8762, and its assets under management stand at HK$3.511 billion.

(Note on scope: the net asset value per unit and assets under management are as of October 15, 2026; the week-to-date change is measured against the closing price of HK$15.850 on October 9.)

On the news front, the 2026 congress of the European Society for Medical Oncology (ESMO) will be held in Madrid, Spain from October 23 to 27; the congress website has disclosed more than 90 late-breaking abstracts (LBA), of which 12 high-value core studies will be presented at the presidential session. A total of 28 Chinese studies have been selected as LBA this time, with 4 entering the presidential oral session — about one third of the core LBA total — and multiple key products from companies including Akeso, Kelun-Biotech and Hutchison Pharma are on the list.

The ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passively managed exchange-traded fund under China Asset Management (Hong Kong), with the investment objective of closely tracking the performance of the Hang Seng Biotech Index. Compiled by Hang Seng Indexes Company on a net total return basis, the index reflects the overall performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, weighted by freefloat-adjusted market capitalisation with a 10% cap on any single constituent.

Industrial Securities said that as licensed-out products enter the commercialisation phase one after another, the sector is expected to gradually shift from valuation-driven to "earnings plus global delivery"-driven, and the 2026 ESMO congress, major business development deals and breakthroughs in new technologies will remain follow-up catalysts.